Literature DB >> 18171730

Activation of TRPA1 by farnesyl thiosalicylic acid.

Michael Maher1, Hong Ao, Tue Banke, Nadia Nasser, Nyan-Tsz Wu, J Guy Breitenbucher, Sandra R Chaplan, Alan D Wickenden.   

Abstract

The nonselective cation channel TRPA1 (ANKTM1, p120) is a potential mediator of pain, and selective pharmacological modulation of this channel may be analgesic. Although several TRPA1 activators exist, these tend to be either reactive or of low potency and/or selectivity. The aim of the present study, therefore, was to identify novel TRPA1 agonists. Using a combination of calcium fluorescent assays and whole-cell electrophysiology, we discovered several compounds that possess potent, selective TRPA1-activating activity, including several lipid compounds (farnesyl thiosalicylic acid, farnesyl thioacetic acid, 15-deoxy-Delta(12,14)-prostaglandin J(2), and 5,8,11,14-eicosatetraynoic acid), and two marketed drugs: disulfiram (Antabuse; a compound used in the treatment of alcohol abuse) and the antifungal agent chlordantoin. Farnesyl thiosalicylic acid activates the channel in excised patches and in the absence of calcium. Furthermore, using a quadruple TRPA1 mutant, we show that the mechanism of action of farnesyl thiosalicylic acid differs from that of the reactive electrophilic reagent allylisothiocyanate. As a TRPA1 agonist with a potentially novel mechanism of action, farnesyl thiosalicylic acid may be useful in the study of TRPA1 channels.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18171730     DOI: 10.1124/mol.107.042663

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  19 in total

Review 1.  TRPs and pain.

Authors:  Yi Dai
Journal:  Semin Immunopathol       Date:  2015-09-15       Impact factor: 9.623

Review 2.  Transient receptor potential (TRP) channels as drug targets for diseases of the digestive system.

Authors:  Peter Holzer
Journal:  Pharmacol Ther       Date:  2011-03-21       Impact factor: 12.310

Review 3.  ThermoTRPs and Pain.

Authors:  Robyn J Laing; Ajay Dhaka
Journal:  Neuroscientist       Date:  2015-01-21       Impact factor: 7.519

Review 4.  The transient receptor potential channel TRPA1: from gene to pathophysiology.

Authors:  Bernd Nilius; Giovanni Appendino; Grzegorz Owsianik
Journal:  Pflugers Arch       Date:  2012-09-22       Impact factor: 3.657

5.  FK506 (tacrolimus) causes pain sensation through the activation of transient receptor potential ankyrin 1 (TRPA1) channels.

Authors:  Tomo Kita; Kunitoshi Uchida; Kenichi Kato; Yoshiro Suzuki; Makoto Tominaga; Jun Yamazaki
Journal:  J Physiol Sci       Date:  2018-11-26       Impact factor: 2.781

6.  Identification of transmembrane domain 5 as a critical molecular determinant of menthol sensitivity in mammalian TRPA1 channels.

Authors:  Bailong Xiao; Adrienne E Dubin; Badry Bursulaya; Veena Viswanath; Timothy J Jegla; Ardem Patapoutian
Journal:  J Neurosci       Date:  2008-09-24       Impact factor: 6.167

7.  How irritating: the role of TRPA1 in sensing cigarette smoke and aerogenic oxidants in the airways.

Authors:  Sidney A Simon; Wolfgang Liedtke
Journal:  J Clin Invest       Date:  2008-07       Impact factor: 14.808

8.  Activation of TRPA1 channels by fenamate nonsteroidal anti-inflammatory drugs.

Authors:  Hongzhen Hu; Jinbin Tian; Yingmin Zhu; Chunbo Wang; Rui Xiao; Jeffrey M Herz; Jackie D Wood; Michael X Zhu
Journal:  Pflugers Arch       Date:  2009-11-04       Impact factor: 3.657

9.  Relative contributions of TRPA1 and TRPV1 channels in the activation of vagal bronchopulmonary C-fibres by the endogenous autacoid 4-oxononenal.

Authors:  T E Taylor-Clark; M A McAlexander; C Nassenstein; S A Sheardown; S Wilson; J Thornton; M J Carr; B J Undem
Journal:  J Physiol       Date:  2008-05-22       Impact factor: 5.182

10.  Modulation of the transient receptor potential channel TRPA1 by phosphatidylinositol 4,5-biphosphate manipulators.

Authors:  Yuji Karashima; Jean Prenen; Victor Meseguer; Grzegorz Owsianik; Thomas Voets; Bernd Nilius
Journal:  Pflugers Arch       Date:  2008-05-07       Impact factor: 3.657

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.